InflaRx (IFRX) director details vested and future stock options

Rhea-AI Filing Summary

InflaRx N.V. director Hege Hellstrom has filed an initial ownership report showing existing stock option holdings in the company. The filing lists four stock option awards over ordinary shares with exercise prices of $4.19, $1.79, $2.41 and $1.17 per share and expirations from May 2033 through January 2036.

Options granted on May 31, 2023, January 5, 2024 and January 3, 2025 covering 22,500, 30,000 and 30,000 underlying ordinary shares are fully vested and exercisable. A further option granted on January 6, 2026 for 30,000 shares will vest in four equal quarterly installments of 7,500 shares, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hellstrom Hege

(Last) (First) (Middle)

C/O INFLARX N.V.

WINZERLAER STREET 2

(Street)

JENA 07745

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
InflaRx N.V. [ IFRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	05/31/2033	Ordinary Shares	22,500	$4.19	D
Stock Option (Right to Buy)	(2)	01/05/2034	Ordinary Shares	30,000	$1.79	D
Stock Option (Right to Buy)	(3)	01/03/2035	Ordinary Shares	30,000	$2.41	D
Stock Option (Right to Buy)	(4)	01/06/2036	Ordinary Shares	30,000	$1.17	D

Explanation of Responses:

1. This option was granted on May 31, 2023 and is fully vested and exercisable as of the date hereof.

2. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

3. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

4. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney

	/s/ Christian Schmid, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does InflaRx (IFRX) director Hege Hellstrom report on this Form 3?

Hege Hellstrom reports existing stock option holdings in InflaRx N.V. The filing lists four stock option grants over ordinary shares with specific exercise prices and expiration dates, establishing her baseline derivative ownership as a company director without showing any new purchases or sales.

How many InflaRx IFRX shares are covered by Hege Hellstrom’s stock options?

The options cover 112,500 underlying ordinary shares in total. This includes 22,500 shares from the 2023 grant and three separate 30,000-share grants from 2024, 2025 and 2026, each with its own exercise price and expiration schedule as disclosed in the filing.

Which of Hege Hellstrom’s InflaRx stock options are already vested?

Options granted on May 31, 2023, January 5, 2024 and January 3, 2025 are fully vested and exercisable. These three awards cover 22,500, 30,000 and 30,000 underlying ordinary shares respectively, meaning all those options can be exercised under their stated terms and prices.

How will the January 6, 2026 InflaRx stock option grant vest for Hege Hellstrom?

The January 6, 2026 option for 30,000 shares will vest in four equal installments. Hellstrom will receive 7,500 vested shares on each quarterly anniversary of the grant date, provided she continues serving through each vesting date, gradually increasing her exercisable position.

What are the exercise prices and expirations of Hege Hellstrom’s InflaRx options?

Her options have exercise prices of $4.19, $1.79, $2.41 and $1.17 per share. The awards expire between May 31, 2033 and January 6, 2036, giving a long-dated window during which the vested portions can be exercised under the specified terms.